Precision Therapeutics Inc., of Minneapolis, completed its merger with Helomics Holding Corp., of Pittsburgh. The latter has become Precision's wholly owned subsidiary. Helomics is focused on women's oncology therapy that deploys the knowledge gained from the patient's own tumor using artificial intelligence technology.